// App-Quantinova.ai

P273 : Efficacy and safety of upadacitinib maintenance treatment for moderate to severe Crohn’s disease: Results from the CELEST study

Researchers

Presenter

  • J Panes

Principal Investigators

  • W J Sandborn

  • E V Loftus Jr

  • G Van Assche

  • S Ghosh

  • Q Zhou

  • S Goteti

  • J V Enejosa

  • A L Pangan

  • A P Lacerda

Medical Centers

  • Hospital Clinic Barcelona, Barcelona, Spain

  • University of California, San Diego, La Jolla, CA

  • Mayo Clinic, Gastroenterology and Hepatology, Rochester, MN

  • University of Birmingham, Birmingham, United Kingdom

  • AbbVie, Inc., North Chicago, IL

Locations

  • Spain

  • United States

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Gastroenterology (GU)

Disease

  • N/A

Biomarkers

  • Plasminogen Activator, Urokinase

  • High sensitivity C-reactive protein

Drug/Treatment

  • ABT-494

Outcome

  • N/A

Study Design

  • Randomized

  • Double Blind/Blinded

  • Open Label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved